Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Leukemia

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 387 articles:
HTML format
Text format



Single Articles


    July 2019
  1. WANG S, Ge M, Cui J, Qiao Z, et al
    Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia.
    Leukemia. 2019 Jul 24. pii: 10.1038/s41375-019-0526.
    PubMed     Text format    


  2. ADVANI PG, Schonfeld SJ, Curtis RE, Dores GM, et al
    Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study.
    Leukemia. 2019 Jul 24. pii: 10.1038/s41375-019-0520.
    PubMed     Text format    


  3. WANG H, Zhao D, Nguyen LX, Wu H, et al
    Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
    Leukemia. 2019 Jul 23. pii: 10.1038/s41375-019-0522.
    PubMed     Text format     Abstract available


  4. CAO J, Cheng H, Shi M, Wang G, et al
    Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Jul 15. pii: 10.1038/s41375-019-0516.
    PubMed     Text format    


  5. DE SMITH AJ, Walsh KM, Morimoto LM, Francis SS, et al
    Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome.
    Leukemia. 2019 Jul 11. pii: 10.1038/s41375-019-0514.
    PubMed     Text format    


    June 2019
  6. BRANFORD S, Kim DDH, Apperley JF, Eide CA, et al
    Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
    Leukemia. 2019 Jun 17. pii: 10.1038/s41375-019-0512.
    PubMed     Text format     Abstract available


  7. STIEF SM, Hanneforth AL, Weser S, Mattes R, et al
    Loss of KDM6A confers drug resistance in acute myeloid leukemia.
    Leukemia. 2019 Jun 14. pii: 10.1038/s41375-019-0497.
    PubMed     Text format     Abstract available


  8. GIMENEZ N, Schulz R, Higashi M, Aymerich M, et al
    Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
    Leukemia. 2019 Jun 13. pii: 10.1038/s41375-019-0507.
    PubMed     Text format     Abstract available


  9. ANGENENDT L, Bormann E, Pabst C, Alla V, et al
    The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
    Leukemia. 2019 Jun 10. pii: 10.1038/s41375-019-0505.
    PubMed     Text format     Abstract available


    May 2019
  10. TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
    Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.
    Leukemia. 2019 May 30. pii: 10.1038/s41375-019-0494.
    PubMed     Text format     Abstract available


  11. ARMENTEROS-MONTERROSO E, Zhao L, Gasparoli L, Brooks T, et al
    The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
    Leukemia. 2019 May 28. pii: 10.1038/s41375-019-0495.
    PubMed     Text format     Abstract available


  12. NII T, Prabhu VV, Ruvolo V, Madhukar N, et al
    Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
    Leukemia. 2019 May 24. pii: 10.1038/s41375-019-0491.
    PubMed     Text format     Abstract available


  13. HOUSHMAND M, Simonetti G, Circosta P, Gaidano V, et al
    Chronic myeloid leukemia stem cells.
    Leukemia. 2019 May 24. pii: 10.1038/s41375-019-0490.
    PubMed     Text format     Abstract available


  14. PAN J, Niu Q, Deng B, Liu S, et al
    CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
    Leukemia. 2019 May 20. pii: 10.1038/s41375-019-0488.
    PubMed     Text format     Abstract available


  15. STILGENBAUER S, Aurran Schleinitz T, Eichhorst B, Lang F, et al
    Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
    Leukemia. 2019 May 14. pii: 10.1038/s41375-019-0475.
    PubMed     Text format    


  16. USTUN C, Le-Rademacher J, Wang HL, Othus M, et al
    Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
    Leukemia. 2019 May 9. pii: 10.1038/s41375-019-0477.
    PubMed     Text format     Abstract available


  17. BATALLER A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G, et al
    The role of TGFbeta in hematopoiesis and myeloid disorders.
    Leukemia. 2019;33:1076-1089.
    PubMed     Text format     Abstract available


  18. POTTER N, Miraki-Moud F, Ermini L, Titley I, et al
    Single cell analysis of clonal architecture in acute myeloid leukaemia.
    Leukemia. 2019;33:1113-1123.
    PubMed     Text format     Abstract available


  19. WANG TT, Yang J, Zhang Y, Zhang M, et al
    IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective gamma-chain cytokines, decreases leukemic T-cell viability.
    Leukemia. 2019;33:1243-1255.
    PubMed     Text format     Abstract available


  20. PAGANO MA, Tibaldi E, Molino P, Frezzato F, et al
    Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.
    Leukemia. 2019;33:1148-1160.
    PubMed     Text format     Abstract available


    April 2019
  21. POLLYEA DA, Tallman MS, de Botton S, Kantarjian HM, et al
    Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0472.
    PubMed     Text format     Abstract available


  22. DONG Y, Zhao X, Feng X, Zhou Y, et al
    SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0456.
    PubMed     Text format     Abstract available


  23. KLEIN K, Witalisz-Siepracka A, Maurer B, Prinz D, et al
    STAT5B(N642H) drives transformation of NKT cells: a novel mouse model for CD56(+) T-LGL leukemia.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0471.
    PubMed     Text format    


  24. LIN M, Nebral K, Gertzen CGW, Ganmore I, et al
    JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0459.
    PubMed     Text format    


  25. HYRENIUS-WITTSTEN A, Pilheden M, Falques-Costa A, Eriksson M, et al
    FLT3(N676K) drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0465.
    PubMed     Text format    


  26. EISENWORT G, Sadovnik I, Schwaab J, Jawhar M, et al
    Identification of a leukemia-initiating stem cell in human mast cell leukemia.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0460.
    PubMed     Text format     Abstract available


  27. CHEN YL, Tang C, Zhang MY, Huang WL, et al
    Blocking ATM-dependent NF-kappaB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia.
    Leukemia. 2019 Apr 2. pii: 10.1038/s41375-019-0458.
    PubMed     Text format     Abstract available


  28. FALINI B, Spinelli O, Meggendorfer M, Martelli MP, et al
    IDH1-R132 changes vary according to NPM1 and other mutations status in AML.
    Leukemia. 2019;33:1043-1047.
    PubMed     Text format    


  29. POTTER N, Jones L, Blair H, Strehl S, et al
    Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.
    Leukemia. 2019;33:893-904.
    PubMed     Text format     Abstract available


  30. ZABORSKY N, Gassner FJ, Hopner JP, Schubert M, et al
    Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
    Leukemia. 2019;33:957-968.
    PubMed     Text format     Abstract available


  31. DORON B, Abdelhamed S, Butler JT, Hashmi SK, et al
    Transmissible ER stress reconfigures the AML bone marrow compartment.
    Leukemia. 2019;33:918-930.
    PubMed     Text format     Abstract available


  32. BAQUERO P, Dawson A, Mukhopadhyay A, Kuntz EM, et al
    Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
    Leukemia. 2019;33:981-994.
    PubMed     Text format     Abstract available


    March 2019
  33. EL-JAWAHRI A, Abel GA, Traeger L, Waldman L, et al
    Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
    Leukemia. 2019 Mar 28. pii: 10.1038/s41375-019-0449.
    PubMed     Text format     Abstract available


  34. JEBARAJ BMC, Tausch E, Landau DA, Bahlo J, et al
    Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.
    Leukemia. 2019 Mar 25. pii: 10.1038/s41375-019-0446.
    PubMed     Text format     Abstract available


  35. VISHWAKARMA BA, Gudmundsson KO, Oakley K, Han Y, et al
    Insertional mutagenesis identifies cooperation between Setbp1 and Mllt3 in inducing myeloid leukemia development.
    Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0445.
    PubMed     Text format    


  36. LUCAS N, Duchmann M, Rameau P, Noel F, et al
    Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.
    Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0447.
    PubMed     Text format     Abstract available


  37. RADPOUR R, Riether C, Simillion C, Hopner S, et al
    CD8(+) T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia.
    Leukemia. 2019 Mar 15. pii: 10.1038/s41375-019-0441.
    PubMed     Text format     Abstract available


  38. JANSSEN L, Frambach SJCM, Allard NAE, Hopman MTE, et al
    Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0443.
    PubMed     Text format    


  39. VENDRAMINI E, Bomben R, Pozzo F, Benedetti D, et al
    KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0444.
    PubMed     Text format    


  40. PFEIFER H, Cazzaniga G, van der Velden VHJ, Cayuela JM, et al
    Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0413.
    PubMed     Text format     Abstract available


  41. BILL M, Papaioannou D, Karunasiri M, Kohlschmidt J, et al
    Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.
    Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0429.
    PubMed     Text format     Abstract available


  42. AKKAPEDDI P, Fragoso R, Hixon JA, Ramalho AS, et al
    A fully human anti-IL-7Ralpha antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 8. pii: 10.1038/s41375-019-0434.
    PubMed     Text format     Abstract available


  43. HE X, Xiao X, Li Q, Jiang Y, et al
    Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0437.
    PubMed     Text format    


  44. CANAANI J, Labopin M, Itala-Remes M, Blaise D, et al
    Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0439.
    PubMed     Text format     Abstract available


  45. BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
    Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0426.
    PubMed     Text format     Abstract available


  46. BASTIAN L, Schroeder MP, Eckert C, Schlee C, et al
    PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 6. pii: 10.1038/s41375-019-0430.
    PubMed     Text format     Abstract available


  47. KOTANI S, Yoda A, Kon A, Kataoka K, et al
    Molecular pathogenesis of disease progression in MLL-rearranged AML.
    Leukemia. 2019;33:612-624.
    PubMed     Text format     Abstract available


  48. KONG G, You X, Wen Z, Chang YI, et al
    Downregulating Notch counteracts Kras(G12D)-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm.
    Leukemia. 2019;33:671-685.
    PubMed     Text format     Abstract available


  49. BENAJIBA L, Alexe G, Su A, Raffoux E, et al
    Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.
    Leukemia. 2019;33:800-804.
    PubMed     Text format    


  50. HUMBERT O, Laszlo GS, Sichel S, Ironside C, et al
    Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.
    Leukemia. 2019;33:762-808.
    PubMed     Text format    


    February 2019
  51. STEINHERZ PG, Seibel NL, Sather H, Ji L, et al
    Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.
    Leukemia. 2019 Feb 28. pii: 10.1038/s41375-019-0422.
    PubMed     Text format     Abstract available


  52. BUENO C, Velasco-Hernandez T, Gutierrez-Aguera F, Zanetti SR, et al
    CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.
    Leukemia. 2019 Feb 18. pii: 10.1038/s41375-019-0418.
    PubMed     Text format    


  53. MCNEER NA, Philip J, Geiger H, Ries RE, et al
    Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.
    Leukemia. 2019 Feb 13. pii: 10.1038/s41375-019-0402.
    PubMed     Text format     Abstract available


  54. MROZEK K, Eisfeld AK, Kohlschmidt J, Carroll AJ, et al
    Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.
    Leukemia. 2019 Feb 8. pii: 10.1038/s41375-019-0390.
    PubMed     Text format     Abstract available


  55. BENARD B, Gentles AJ, Kohnke T, Majeti R, et al
    Data mining for mutation-specific targets in acute myeloid leukemia.
    Leukemia. 2019 Feb 6. pii: 10.1038/s41375-019-0387.
    PubMed     Text format     Abstract available


  56. GUENOT C, Lacombe F, Allou K, Dumezy F, et al
    Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.
    Leukemia. 2019 Feb 5. pii: 10.1038/s41375-019-0393.
    PubMed     Text format    


  57. DAVER N, Schlenk RF, Russell NH, Levis MJ, et al
    Targeting FLT3 mutations in AML: review of current knowledge and evidence.
    Leukemia. 2019;33:299-312.
    PubMed     Text format     Abstract available


  58. HOURIGAN CS, Gale RP, Walter RB
    Refining AML outcome prediction.
    Leukemia. 2019;33:283-284.
    PubMed     Text format    


  59. HERNANDEZ-SANCHEZ M, Kotaskova J, Rodriguez AE, Radova L, et al
    CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase.
    Leukemia. 2019;33:518-558.
    PubMed     Text format    


  60. BORGA C, Park G, Foster C, Burroughs-Garcia J, et al
    Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis.
    Leukemia. 2019;33:333-347.
    PubMed     Text format     Abstract available


  61. CERNA K, Oppelt J, Chochola V, Musilova K, et al
    MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
    Leukemia. 2019;33:403-414.
    PubMed     Text format     Abstract available


  62. ENGEL N, Rovo A, Badoglio M, Labopin M, et al
    European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation.
    Leukemia. 2019;33:508-517.
    PubMed     Text format     Abstract available


  63. KAMPEN KR, Sulima SO, Verbelen B, Girardi T, et al
    The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
    Leukemia. 2019;33:319-332.
    PubMed     Text format     Abstract available


    January 2019
  64. MASCHMEYER G, De Greef J, Mellinghoff SC, Nosari A, et al
    Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).
    Leukemia. 2019 Jan 30. pii: 10.1038/s41375-019-0388.
    PubMed     Text format     Abstract available


  65. CHEN R, Zhu M, Chaudhari RR, Robles O, et al
    Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
    Leukemia. 2019 Jan 30. pii: 10.1038/s41375-018-0364.
    PubMed     Text format     Abstract available


  66. SHI Y, Wang G, Muhowski EM, McCaw L, et al
    Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
    Leukemia. 2019 Jan 29. pii: 10.1038/s41375-019-0381.
    PubMed     Text format     Abstract available


  67. SCHMIDT L, Heyes E, Scheiblecker L, Eder T, et al
    CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-019-0382.
    PubMed     Text format     Abstract available


  68. KROMBHOLZ CF, Gallego-Villar L, Sahoo SS, Panda PK, et al
    Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0343.
    PubMed     Text format    


  69. MOYSIADIS T, Baliakas P, Rossi D, Catherwood M, et al
    Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen b-receptors.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0322.
    PubMed     Text format    


  70. KOLLMANN S, Grundschober E, Maurer B, Warsch W, et al
    Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0369.
    PubMed     Text format     Abstract available


  71. HOFFMANN H, Thiede C, Glauche I, Kramer M, et al
    The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0371.
    PubMed     Text format    


  72. NABINGER SC, Chen S, Gao R, Yao C, et al
    Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-019-0377.
    PubMed     Text format    


  73. BACCARANI M, Castagnetti F, Gugliotta G, Rosti G, et al
    The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0341.
    PubMed     Text format     Abstract available


  74. ESTEY E, Othus M, Gale RP
    New study-designs to address the clinical complexity of acute myeloid leukemia.
    Leukemia. 2019 Jan 22. pii: 10.1038/s41375-018-0363.
    PubMed     Text format    


  75. FIORCARI S, Benatti S, Zucchetto A, Zucchini P, et al
    Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS.
    Leukemia. 2019 Jan 18. pii: 10.1038/s41375-018-0296.
    PubMed     Text format    


  76. ALFONSO V, Iaccarino L, Ottone T, Cicconi L, et al
    Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
    Leukemia. 2019 Jan 16. pii: 10.1038/s41375-018-0298.
    PubMed     Text format    


  77. LOPEZ-MILLAN B, Sanchez-Martinez D, Roca-Ho H, Gutierrez-Aguera F, et al
    NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0353.
    PubMed     Text format     Abstract available


  78. JAWHAR M, Dohner K, Kreil S, Schwaab J, et al
    KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0346.
    PubMed     Text format     Abstract available


  79. REDA G, Cassin R, Gentile M, Mauro FR, et al
    IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0344.
    PubMed     Text format    


  80. OZTURK S, Roessner PM, Schulze-Edinghausen L, Yazdanparast H, et al
    Rejection of adoptively transferred Emicro-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0332.
    PubMed     Text format    


  81. HOANG VT, Verma D, Godavarthy PS, Llavona P, et al
    The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0358.
    PubMed     Text format     Abstract available


  82. GOUNARI M, Ntoufa S, Gerousi M, Vilia MG, et al
    Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
    Leukemia. 2019 Jan 3. pii: 10.1038/s41375-018-0335.
    PubMed     Text format    


  83. NIYONGERE S, Lucas N, Zhou JM, Sansil S, et al
    Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.
    Leukemia. 2019;33:205-216.
    PubMed     Text format     Abstract available


  84. DWIVEDI P, Muench DE, Wagner M, Azam M, et al
    Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.
    Leukemia. 2019;33:75-87.
    PubMed     Text format     Abstract available


  85. HAUBNER S, Perna F, Kohnke T, Schmidt C, et al
    Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
    Leukemia. 2019;33:64-74.
    PubMed     Text format     Abstract available


  86. ARAKI M, Yang Y, Imai M, Mizukami Y, et al
    Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
    Leukemia. 2019;33:122-131.
    PubMed     Text format     Abstract available


  87. SCHNEIDT V, Ilecka M, Dreger P, van Zyl DG, et al
    Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo.
    Leukemia. 2019;33:88-98.
    PubMed     Text format     Abstract available


  88. FRASZCZAK J, Vadnais C, Rashkovan M, Ross J, et al
    Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice.
    Leukemia. 2019;33:110-121.
    PubMed     Text format     Abstract available


  89. SHIMONI A, Labopin M, Lorentino F, Van Lint MT, et al
    Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
    Leukemia. 2019;33:230-239.
    PubMed     Text format     Abstract available


    December 2018
  90. ZHAO J, Liang JW, Xue HL, Shen SH, et al
    The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
    Leukemia. 2018 Dec 21. pii: 10.1038/s41375-018-0338.
    PubMed     Text format     Abstract available


  91. VELAZQUEZ-AVILA M, Balandran JC, Ramirez-Ramirez D, Velazquez-Avila M, et al
    High cortactin expression in B-cell acute lymphoblastic leukemia is associated with increased transendothelial migration and bone marrow relapse.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0333.
    PubMed     Text format     Abstract available


  92. SCHETELIG J, de Wreede LC, van Gelder M, Koster L, et al
    Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0302.
    PubMed     Text format     Abstract available


  93. EFFICACE F, Breccia M, Avvisati G, Cottone F, et al
    Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0325.
    PubMed     Text format     Abstract available


  94. BORGA C, Foster CA, Iyer S, Garcia SP, et al
    Molecularly distinct models of zebrafish Myc-induced B cell leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0328.
    PubMed     Text format    


  95. HANNA BS, Roessner PM, Scheffold A, Jebaraj BMC, et al
    PI3Kdelta inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0318.
    PubMed     Text format     Abstract available


  96. VON TRESCKOW J, Cramer P, Bahlo J, Robrecht S, et al
    CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0313.
    PubMed     Text format     Abstract available


  97. KIVIOJA JL, Thanasopoulou A, Kumar A, Kontro M, et al
    Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0327.
    PubMed     Text format     Abstract available


  98. REEDIJK AMJ, Klein K, Coebergh JWW, Kremer LC, et al
    Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0314.
    PubMed     Text format     Abstract available


  99. HASAN MK, Rassenti L, Widhopf GF 2nd, Yu J, et al
    Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0306.
    PubMed     Text format     Abstract available


  100. CORTES JE, Heidel FH, Hellmann A, Fiedler W, et al
    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0312.
    PubMed     Text format     Abstract available


  101. PARK JH, Woo YM, Youm EM, Hamad N, et al
    HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0321.
    PubMed     Text format     Abstract available


  102. TEN HACKEN E, Gounari M, Ghia P, Burger JA, et al
    The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0303.
    PubMed     Text format     Abstract available


  103. MODVIG S, Madsen HO, Siitonen SM, Rosthoj S, et al
    Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 14. pii: 10.1038/s41375-018-0307.
    PubMed     Text format     Abstract available


  104. SCHERR M, Kirchhoff H, Battmer K, Wohlan K, et al
    Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0315.
    PubMed     Text format     Abstract available


  105. ANDERSEN MA, Moser CE, Lundgren J, Niemann CU, et al
    Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0316.
    PubMed     Text format     Abstract available


  106. ZEIJLEMAKER W, Grob T, Meijer R, Hanekamp D, et al
    CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
    Leukemia. 2018 Dec 12. pii: 10.1038/s41375-018-0326.
    PubMed     Text format     Abstract available


  107. HU X, Xu S, Chen Y, Gao Z, et al
    Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis.
    Leukemia. 2018 Dec 5. pii: 10.1038/s41375-018-0301.
    PubMed     Text format     Abstract available


    November 2018
  108. BLAGITKO-DORFS N, Schlosser P, Greve G, Pfeifer D, et al
    Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
    Leukemia. 2018 Nov 23. pii: 10.1038/s41375-018-0293.
    PubMed     Text format     Abstract available


    October 2018
  109. CAESER R, Collord G, Yao WQ, Chen Z, et al
    Targeting MEK in vemurafenib-resistant hairy cell leukemia.
    Leukemia. 2018 Oct 19. pii: 10.1038/s41375-018-0270.
    PubMed     Text format    


  110. KRAFT B, Lombard J, Kirsch M, Wuchter P, et al
    SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia.
    Leukemia. 2018 Oct 15. pii: 10.1038/s41375-018-0287.
    PubMed     Text format    


  111. FRASER G, Cramer P, Demirkan F, Silva RS, et al
    Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
    PubMed     Text format     Abstract available


  112. OTHUS M, Sekeres MA, Nand S, Garcia-Manero G, et al
    Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0275.
    PubMed     Text format     Abstract available


  113. OTHUS M, Estey EH, Garcia-Manero G, Wood BL, et al
    Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0274.
    PubMed     Text format    


  114. ROSS DM, Pagani IS, Shanmuganathan N, Kok CH, et al
    Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0264.
    PubMed     Text format     Abstract available


  115. MANSO BA, Zhang H, Mikkelson MG, Gwin KA, et al
    Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0280.
    PubMed     Text format     Abstract available


  116. YAN B, Chen Q, Shimada K, Tang M, et al
    Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0279.
    PubMed     Text format     Abstract available


  117. WALKER CJ, Oakes CC, Genutis LK, Giacopelli B, et al
    Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0281.
    PubMed     Text format    


  118. BRAESS J, Amler S, Kreuzer KA, Spiekermann K, et al
    Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0268.
    PubMed     Text format     Abstract available


  119. DOHNER H, Dolnik A, Tang L, Seymour JF, et al
    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0257.
    PubMed     Text format     Abstract available


  120. VANDEPOELE K, Van der Meulen J, Denys B
    The NF1 hotspot in acute myeloid leukemia: what's in a name?
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0266.
    PubMed     Text format    


    September 2018
  121. BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
    Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0265.
    PubMed     Text format     Abstract available


  122. HANNA BS, Roessner PM, Yazdanparast H, Colomer D, et al
    Control of chronic lymphocytic leukemia development by clonally-expanded CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues.
    Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0250.
    PubMed     Text format     Abstract available


  123. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
    Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0237.
    PubMed     Text format     Abstract available


  124. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
    Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0241.
    PubMed     Text format     Abstract available


  125. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2018 Sep 14. pii: 10.1038/s41375-018-0236.
    PubMed     Text format     Abstract available


  126. KLUPSCH K, Baeriswyl V, Scholz R, Dannenberg J, et al
    COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
    Leukemia. 2018 Sep 11. pii: 10.1038/s41375-018-0249.
    PubMed     Text format    


  127. MOUJALLED DM, Pomilio G, Ghiurau C, Ivey A, et al
    Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0261.
    PubMed     Text format     Abstract available


  128. AGHEL N, Delgado DH, Lipton JH
    Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
    Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0247.
    PubMed     Text format     Abstract available


    August 2018
  129. TAKESHITA A, Asou N, Atsuta Y, Sakura T, et al
    Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.
    Leukemia. 2018 Aug 9. pii: 10.1038/s41375-018-0233.
    PubMed     Text format     Abstract available


  130. DUPLOYEZ N, Marceau-Renaut A, Villenet C, Petit A, et al
    The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Leukemia. 2018 Aug 8. pii: 10.1038/s41375-018-0227.
    PubMed     Text format     Abstract available


  131. PATNAIK MM, Tefferi A, Garcia-Manero G
    Blast-phase chronic myelomonocytic leukemia: more than just semantics.
    Leukemia. 2018 Aug 7. pii: 10.1038/s41375-018-0228.
    PubMed     Text format    


  132. KURTZ SE, Eide CA, Kaempf A, Mori M, et al
    Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.
    Leukemia. 2018 Aug 6. pii: 10.1038/s41375-018-0225.
    PubMed     Text format    


    July 2018
  133. LEEKSMA AC, Taylor J, Wu B, Gardner JR, et al
    Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
    Leukemia. 2018 Jul 23. pii: 10.1038/s41375-018-0215.
    PubMed     Text format     Abstract available


  134. KREITMAN RJ, Dearden C, Zinzani PL, Delgado J, et al
    Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
    Leukemia. 2018 Jul 20. pii: 10.1038/s41375-018-0210.
    PubMed     Text format     Abstract available


  135. ALDOSS I, Capelletti M, Park J, Pistofidis RS, et al
    Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.
    Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0213.
    PubMed     Text format     Abstract available


  136. CICCONI L, Fenaux P, Kantarjian H, Tallman M, et al
    Molecular remission as a therapeutic objective in acute promyelocytic leukemia.
    Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0219.
    PubMed     Text format     Abstract available


  137. LI Z, He S, Look AT
    The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
    Leukemia. 2018 Jul 15. pii: 10.1038/s41375-018-0201.
    PubMed     Text format    


  138. L'ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2018 Jul 9. pii: 10.1038/s41375-018-0177.
    PubMed     Text format     Abstract available


  139. STUDD JB, Yang M, Li Z, Vijayakrishnan J, et al
    Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism.
    Leukemia. 2018 Jul 6. pii: 10.1038/s41375-018-0184.
    PubMed     Text format     Abstract available


  140. LUNDIN-STROM KB, Biloglav A, Lilljebjorn H, Rissler M, et al
    Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Jul 2. pii: 10.1038/s41375-018-0191.
    PubMed     Text format    


    June 2018
  141. VICENTE-DUENAS C, Gonzalez-Herrero I, Sehgal L, Garcia-Ramirez I, et al
    Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia.
    Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0192.
    PubMed     Text format    


  142. MARGOLSKEE E
    So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology.
    Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0186.
    PubMed     Text format    


  143. BOND J, Labis E, Marceau-Renaut A, Duployez N, et al
    Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.
    Leukemia. 2018 Jun 27. pii: 10.1038/s41375-018-0187.
    PubMed     Text format    


  144. HOLMQVIST AS, Chen Y, Wu J, Kung M, et al
    Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.
    Leukemia. 2018 Jun 26. pii: 10.1038/s41375-018-0171.
    PubMed     Text format    


  145. CRIADO I, Blanco E, Rodriguez-Caballero A, Alcoceba M, et al
    Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.
    Leukemia. 2018 Jun 21. pii: 10.1038/s41375-018-0164.
    PubMed     Text format    


  146. SUTTORP M, Schulze P, Glauche I, Gohring G, et al
    Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0179.
    PubMed     Text format     Abstract available


  147. GEBHARD C, Glatz D, Schwarzfischer L, Wimmer J, et al
    Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0165.
    PubMed     Text format     Abstract available


  148. ERNST T, Busch M, Rinke J, Ernst J, et al
    Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.
    Leukemia. 2018 Jun 13. pii: 10.1038/s41375-018-0157.
    PubMed     Text format    


  149. BODDU P, Gurguis C, Sanford D, Cortes J, et al
    Response kinetics and factors predicting survival in core-binding factor leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0158.
    PubMed     Text format    


  150. BOUDREAUX SP, Duren RP, Call SG, Nguyen L, et al
    Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0174.
    PubMed     Text format     Abstract available


  151. TASIAN SK, Casas JA, Posocco D, Gandre-Babbe S, et al
    Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0169.
    PubMed     Text format     Abstract available


  152. TIMILSHINA N, Breunis H, Tomlinson GA, Brandwein JM, et al
    Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0162.
    PubMed     Text format     Abstract available


  153. BARGHOUT SH, Patel PS, Wang X, Xu GW, et al
    Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0167.
    PubMed     Text format     Abstract available


  154. EISFELD AK, Kohlschmidt J, Mrozek K, Mims A, et al
    NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
    Leukemia. 2018 Jun 5. pii: 10.1038/s41375-018-0147.
    PubMed     Text format     Abstract available


  155. DONG X, Zhang W, Wu H, Huang J, et al
    Structural basis of DUX4/IGH-driven transactivation.
    Leukemia. 2018;32:1466-1476.
    PubMed     Text format     Abstract available


  156. INOUE D, Fujino T, Sheridan P, Zhang YZ, et al
    A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.
    Leukemia. 2018;32:1327-1337.
    PubMed     Text format     Abstract available


  157. VERBIEST T, Finnon R, Brown N, Cruz-Garcia L, et al
    Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis.
    Leukemia. 2018;32:1435-1444.
    PubMed     Text format     Abstract available


  158. ZHENG L, Xu L, Xu Q, Yu L, et al
    Utx loss causes myeloid transformation.
    Leukemia. 2018;32:1458-1465.
    PubMed     Text format     Abstract available


    May 2018
  159. CHEUNG LC, Tickner J, Hughes AM, Skut P, et al
    New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
    Leukemia. 2018 May 8. pii: 10.1038/s41375-018-0144.
    PubMed     Text format     Abstract available


  160. MEGGENDORFER M, Cappelli LV, Walter W, Haferlach C, et al
    IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.
    Leukemia. 2018;32:1249-1253.
    PubMed     Text format    


  161. DAVIDSSON J, Puschmann A, Tedgard U, Bryder D, et al
    SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.
    Leukemia. 2018;32:1106-1115.
    PubMed     Text format     Abstract available


  162. ZHENG W, O'Hear CE, Alli R, Basham JH, et al
    PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
    Leukemia. 2018;32:1157-1167.
    PubMed     Text format     Abstract available


  163. JETANI H, Garcia-Cadenas I, Nerreter T, Thomas S, et al
    CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib.
    Leukemia. 2018;32:1168-1179.
    PubMed     Text format     Abstract available


  164. ZAMPINI M, Tregnago C, Bisio V, Simula L, et al
    Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.
    Leukemia. 2018;32:1124-1134.
    PubMed     Text format     Abstract available


  165. WONG ACH, Rasko JEJ, Wong JJ
    We skip to work: alternative splicing in normal and malignant myelopoiesis.
    Leukemia. 2018;32:1081-1093.
    PubMed     Text format     Abstract available


  166. TEFFERI A, Mudireddy M, Mannelli F, Begna KH, et al
    Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.
    Leukemia. 2018;32:1200-1210.
    PubMed     Text format     Abstract available


    April 2018
  167. PATNAIK MM, Pierola AA, Vallapureddy R, Yalniz FF, et al
    Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0143.
    PubMed     Text format    


  168. HUITING LN, Samaha Y, Zhang GL, Roderick JE, et al
    UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0141.
    PubMed     Text format     Abstract available


  169. XIAO W, Rampal R, Zhang Y, Cimera R, et al
    JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0145.
    PubMed     Text format    


  170. KAYSER S, Schlenk RF, Platzbecker U
    Management of patients with acute promyelocytic leukemia.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0139.
    PubMed     Text format     Abstract available


  171. GARCIA EG, Iyer S, Garcia SP, Loontiens S, et al
    Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0130.
    PubMed     Text format    


  172. RENNEVILLE A, Attias P, Thomas X, Bally C, et al
    Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0137.
    PubMed     Text format    


  173. DE BIE J, Demeyer S, Alberti-Servera L, Geerdens E, et al
    Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0127.
    PubMed     Text format     Abstract available


  174. PASCHKA P, Schlenk RF, Weber D, Benner A, et al
    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0129.
    PubMed     Text format     Abstract available


  175. STUDENCKA-TURSKI M, Maubach G, Feige MH, Naumann M, et al
    Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0128.
    PubMed     Text format    


  176. WARTIOVAARA-KAUTTO U, Hirvonen EAM, Pitkanen E, Heckman C, et al
    Germline alterations in a consecutive series of acute myeloid leukemia.
    Leukemia. 2018 Apr 10. pii: 10.1038/s41375-018-0049.
    PubMed     Text format    


  177. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2018 Apr 7. pii: 10.1038/s41375-018-0032.
    PubMed     Text format    


  178. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Text format     Abstract available


  179. PATNAIK MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, et al
    A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0121.
    PubMed     Text format    


  180. PETER B, Bibi S, Eisenwort G, Wingelhofer B, et al
    Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Leukemia. 2018;32:1016-1022.
    PubMed     Text format     Abstract available


  181. MAURA F, Petljak M, Lionetti M, Cifola I, et al
    Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
    Leukemia. 2018;32:1044-1048.
    PubMed     Text format    


  182. SANARICO AG, Ronchini C, Croce A, Memmi EM, et al
    The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.
    Leukemia. 2018;32:911-919.
    PubMed     Text format     Abstract available


  183. MARSILIO S, Khiabanian H, Fabbri G, Vergani S, et al
    Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.
    Leukemia. 2018;32:1041-1044.
    PubMed     Text format    


    March 2018
  184. HOSSEINI MM, Kurtz SE, Abdelhamed S, Mahmood S, et al
    Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
    Leukemia. 2018 Mar 29. pii: 10.1038/s41375-018-0112.
    PubMed     Text format     Abstract available


  185. THAN H, Qiao Y, Huang X, Yan D, et al
    Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0050.
    PubMed     Text format    


  186. HOJJAT-FARSANGI M, Daneshmanesh AH, Khan AS, Shetye J, et al
    First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0113.
    PubMed     Text format    


  187. THI NGOC PC, Tan SH, Tan TK, Chan MM, et al
    Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0110.
    PubMed     Text format     Abstract available


  188. GHIA P, Rawstron A
    Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0109.
    PubMed     Text format     Abstract available


  189. KUCHENBAUER F, Buske C
    Revisiting thrombocytopenia in acute promyelocytic leukemia.
    Leukemia. 2018 Mar 23. pii: 10.1038/s41375-018-0105.
    PubMed     Text format    


  190. RUDAT S, Pfaus A, Cheng YY, Holtmann J, et al
    RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
    Leukemia. 2018 Mar 22. pii: 10.1038/s41375-018-0102.
    PubMed     Text format     Abstract available


  191. GENTILE M, Shanafelt TD, Reda G, Mauro FR, et al
    Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0100.
    PubMed     Text format    


  192. BURNS MA, Liao ZW, Yamagata N, Pouliot GP, et al
    Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0097.
    PubMed     Text format     Abstract available


  193. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Text format     Abstract available


  194. QIN YZ, Huang XJ, Zhu HH
    Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Leukemia. 2018 Mar 14. pii: 10.1038/s41375-018-0095.
    PubMed     Text format    


  195. GUNNARSSON R, Dilorenzo S, Lundin-Strom KB, Olsson L, et al
    Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 12. pii: 10.1038/s41375-018-0092.
    PubMed     Text format     Abstract available


  196. KELLY AD, Madzo J, Madireddi P, Kropf P, et al
    Demethylator phenotypes in acute myeloid leukemia.
    Leukemia. 2018 Mar 7. pii: 10.1038/s41375-018-0084.
    PubMed     Text format     Abstract available


  197. GERBOTH S, Frittoli E, Palamidessi A, Baltanas FC, et al
    Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
    Leukemia. 2018;32:820-827.
    PubMed     Text format     Abstract available


  198. ANDERSSON EI, Putzer S, Yadav B, Dufva O, et al
    Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Leukemia. 2018;32:774-787.
    PubMed     Text format     Abstract available


    February 2018
  199. TAWANA K, Drazer MW, Churpek JE
    Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0051.
    PubMed     Text format     Abstract available


  200. MARUFFI M, Sposto R, Oberley MJ, Kysh L, et al
    Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0058.
    PubMed     Text format     Abstract available


  201. SAUSSELE S, Hehlmann R, Fabarius A, Jeromin S, et al
    Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
    Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0055.
    PubMed     Text format     Abstract available


  202. ALI A, Penneroux J, Dal Bello R Jr, Masse A, et al
    Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
    Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0076.
    PubMed     Text format    


  203. PETROV JC, Wada M, Pinz KG, Yan LE, et al
    Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0075.
    PubMed     Text format     Abstract available


  204. HNIZDA A, Fabry M, Moriyama T, Pachl P, et al
    Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0073.
    PubMed     Text format     Abstract available


  205. EISFELD AK, Kohlschmidt J, Mrozek K, Blachly JS, et al
    Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0068.
    PubMed     Text format     Abstract available


  206. BICCLER JL, Ostgard LSG, Severinsen MT, Marcher CW, et al
    Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0054.
    PubMed     Text format    


  207. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
    Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0034.
    PubMed     Text format     Abstract available


  208. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
    Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0039.
    PubMed     Text format     Abstract available


  209. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
    Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0035.
    PubMed     Text format     Abstract available


  210. LAVALLEE VP, Chagraoui J, MacRae T, Marquis M, et al
    Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0069.
    PubMed     Text format     Abstract available


  211. DAVER N, Boddu P, Garcia-Manero G, Yadav SS, et al
    Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0070.
    PubMed     Text format     Abstract available


  212. L ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0033.
    PubMed     Text format     Abstract available


  213. RASCHE M, Zimmermann M, Borschel L, Bourquin JP, et al
    Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0071.
    PubMed     Text format     Abstract available


  214. STRATI P, Ferrajoli A, Wierda WG, Jain N, et al
    Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
    Leukemia. 2018 Feb 20. pii: 10.1038/s41375-018-0059.
    PubMed     Text format    


  215. CRAMER SD, Hixon JA, Andrews C, Porter RJ, et al
    Mutant IL-7Ralpha and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.
    Leukemia. 2018 Feb 15. pii: 10.1038/s41375-017-0001.
    PubMed     Text format    


  216. SUAREZ-GONZALEZ J, Martinez-Laperche C, Martinez N, Rodriguez-Macias G, et al
    Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis.
    Leukemia. 2018 Feb 5. pii: 10.1038/s41375-018-0042.
    PubMed     Text format    


  217. PENG D, Wang H, Li L, Ma X, et al
    miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0015.
    PubMed     Text format     Abstract available


  218. LA STARZA R, Messina M, Gianfelici V, Pierini V, et al
    High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0031.
    PubMed     Text format    


  219. WINGELHOFER B, Maurer B, Heyes EC, Cumaraswamy AA, et al
    Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0005.
    PubMed     Text format     Abstract available


  220. MALCIKOVA J, Tausch E, Rossi D, Sutton LA, et al
    ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0007.
    PubMed     Text format     Abstract available


  221. BALASUBRAMANIAN SK, Aly M, Nagata Y, Bat T, et al
    Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.
    Leukemia. 2018;32:550-553.
    PubMed     Text format    


  222. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
    Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
    Leukemia. 2018;32:364-375.
    PubMed     Text format     Abstract available


  223. STENGEL A, Kern W, Meggendorfer M, Nadarajah N, et al
    Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.
    Leukemia. 2018;32:295-302.
    PubMed     Text format     Abstract available


  224. KUBESOVA B, Pavlova S, Malcikova J, Kabathova J, et al
    Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
    Leukemia. 2018;32:450-461.
    PubMed     Text format     Abstract available


  225. DEANGELO DJ, George TI, Linder A, Langford C, et al
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
    Leukemia. 2018;32:470-478.
    PubMed     Text format     Abstract available


  226. LIU E, Tong Y, Dotti G, Shaim H, et al
    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Leukemia. 2018;32:520-531.
    PubMed     Text format     Abstract available


  227. MEYER C, Burmeister T, Groger D, Tsaur G, et al
    The MLL recombinome of acute leukemias in 2017.
    Leukemia. 2018;32:273-284.
    PubMed     Text format     Abstract available


  228. GARRIDO CASTRO P, van Roon EHJ, Pinhancos SS, Trentin L, et al
    The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Leukemia. 2018;32:323-331.
    PubMed     Text format     Abstract available


  229. KAUSHIK S, Liu F, Veazey KJ, Gao G, et al
    Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
    Leukemia. 2018;32:499-509.
    PubMed     Text format     Abstract available


    January 2018
  230. SUN X, Ren Y, Gunawan S, Teng P, et al
    Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099.
    Leukemia. 2018 Jan 30. pii: 10.1038/s41375-018-0020.
    PubMed     Text format    


  231. JO S, Lee JH, Mattei JJ, Barrett DM, et al
    Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
    Leukemia. 2018 Jan 5. pii: leu2017312. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  232. PIETTE C, Suciu S, Clappier E, Bertrand Y, et al
    Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.
    Leukemia. 2018;32:244-248.
    PubMed     Text format    


  233. BUONTEMPO F, McCubrey JA, Orsini E, Ruzzene M, et al
    Therapeutic targeting of CK2 in acute and chronic leukemias.
    Leukemia. 2018;32:1-10.
    PubMed     Text format     Abstract available


  234. BRAZDILOVA K, Plevova K, Skuhrova Francova H, Kockova H, et al
    Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.
    Leukemia. 2018;32:234-236.
    PubMed     Text format    


  235. BODDU P, Jorgensen J, Kantarjian H, Borthakur G, et al
    Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
    Leukemia. 2018;32:241-244.
    PubMed     Text format    


  236. GU S, Sayad A, Chan G, Yang W, et al
    SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Leukemia. 2018;32:203-213.
    PubMed     Text format     Abstract available


  237. MINGAY M, Chaturvedi A, Bilenky M, Cao Q, et al
    Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia.
    Leukemia. 2018;32:11-20.
    PubMed     Text format     Abstract available


  238. GOLE B, Mian E, Rall M, Wiesmuller L, et al
    Base excision repair proteins couple activation-induced cytidine deaminase and endonuclease G during replication stress-induced MLL destabilization.
    Leukemia. 2018;32:159-167.
    PubMed     Text format     Abstract available


  239. BROWN JR, Hillmen P, O'Brien S, Barrientos JC, et al
    Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
    Leukemia. 2018;32:83-91.
    PubMed     Text format     Abstract available


  240. VILLARESE P, Lours C, Trinquand A, Le Noir S, et al
    TCRalpha rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.
    Leukemia. 2018;32:61-71.
    PubMed     Text format     Abstract available


  241. SUN L, Shi Y, Wang G, Wang X, et al
    PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
    Leukemia. 2018;32:184-193.
    PubMed     Text format     Abstract available


  242. WELSH SJ, Churchman ML, Togni M, Mullighan CG, et al
    Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
    Leukemia. 2018;32:38-48.
    PubMed     Text format     Abstract available


    December 2017
  243. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
    Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).
    Leukemia. 2017 Dec 18. pii: leu2017341. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  244. BU J, Chen A, Yan X, He F, et al
    SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
    Leukemia. 2017 Dec 18. pii: leu2017339. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  245. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
    Chromothripsis in acute myeloid leukemia: Biological features and impact on survival.
    Leukemia. 2017 Dec 18. pii: leu2017351. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  246. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
    Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Leukemia. 2017 Dec 18. pii: leu2017350. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  247. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2017 Dec 12. pii: leu2017349. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  248. TIRADO-GONZALEZ I, Czlonka E, Nevmerzhitskaya A, Soetopo D, et al
    CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.
    Leukemia. 2017 Dec 6. pii: leu2017346. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  249. DRIESSEN EMC, de Lorenzo P, Campbell M, Felice M, et al
    Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.
    Leukemia. 2017;31:2854.
    PubMed     Text format     Abstract available


  250. GRZES KM, Swamy M, Hukelmann JL, Emslie E, et al
    Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
    Leukemia. 2017;31:2771-2779.
    PubMed     Text format     Abstract available


  251. GARCIA-MANERO G, Sekeres MA, Egyed M, Breccia M, et al
    A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts.
    Leukemia. 2017;31:2799-2806.
    PubMed     Text format     Abstract available


  252. TESIO M, Trinquand A, Ballerini P, Hypolite G, et al
    Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.
    Leukemia. 2017;31:2594-2600.
    PubMed     Text format     Abstract available


  253. ELDER A, Bomken S, Wilson I, Blair HJ, et al
    Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.
    Leukemia. 2017;31:2577-2586.
    PubMed     Text format     Abstract available


  254. DELGADO-MARTIN C, Meyer LK, Huang BJ, Shimano KA, et al
    JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Leukemia. 2017;31:2568-2576.
    PubMed     Text format     Abstract available


  255. RASCHE M, von Neuhoff C, Dworzak M, Bourquin JP, et al
    Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.
    Leukemia. 2017;31:2807-2814.
    PubMed     Text format     Abstract available


  256. ZHANG H, Reister Schultz A, Luty S, Rofelty A, et al
    Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.
    Leukemia. 2017;31:2752-2760.
    PubMed     Text format     Abstract available


  257. LYU Y, Lou J, Yang Y, Feng J, et al
    Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
    Leukemia. 2017;31:2543-2551.
    PubMed     Text format     Abstract available


  258. YOKOTA A, Hirai H, Shoji T, Maekawa T, et al
    Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.
    Leukemia. 2017;31:2742-2751.
    PubMed     Text format     Abstract available


    November 2017
  259. LABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2017 Nov 28. pii: leu2017337. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  260. NIMMAGADDA SC, Frey S, Edelmann B, Hellmich C, et al
    Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
    Leukemia. 2017 Nov 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  261. LHERMITTE L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, et al
    Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.
    Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  262. WALF-VORDERWULBECKE V, Pearce K, Brooks T, Hubank M, et al
    Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
    Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  263. HADZIJUSUFOVIC E, Albrecht-Schgoer K, Huber K, Hoermann G, et al
    Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
    Leukemia. 2017;31:2388-2397.
    PubMed     Text format     Abstract available


  264. PULIKKAN JA, Tenen DG, Behre G
    C/EBPalpha deregulation as a paradigm for leukemogenesis.
    Leukemia. 2017;31:2279-2285.
    PubMed     Text format     Abstract available


  265. LIU X, Rothe K, Yen R, Fruhstorfer C, et al
    A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.
    Leukemia. 2017;31:2376-2387.
    PubMed     Text format     Abstract available


  266. THIEL VN, Giaimo BD, Schwarz P, Soller K, et al
    Heterodimerization of AML1/ETO with CBFbeta is required for leukemogenesis but not for myeloproliferation.
    Leukemia. 2017;31:2491-2502.
    PubMed     Text format     Abstract available


  267. O'LEARY HA, Capitano M, Cooper S, Mantel C, et al
    DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.
    Leukemia. 2017;31:2468-2478.
    PubMed     Text format     Abstract available


  268. HOWARD DR, Munir T, McParland L, Rawstron AC, et al
    Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
    Leukemia. 2017;31:2416-2425.
    PubMed     Text format     Abstract available


  269. SAVINO AM, Sarno J, Trentin L, Vieri M, et al
    The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
    Leukemia. 2017;31:2365-2375.
    PubMed     Text format     Abstract available


  270. KRAMER AC, Kothari A, Wilson WC, Celik H, et al
    Dnmt3a regulates T-cell development and suppresses T-ALL transformation.
    Leukemia. 2017;31:2479-2490.
    PubMed     Text format     Abstract available


  271. ABRAHAM M, Klein S, Bulvik B, Wald H, et al
    The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
    Leukemia. 2017;31:2336-2346.
    PubMed     Text format     Abstract available


  272. HA VL, Luong A, Li F, Casero D, et al
    The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.
    Leukemia. 2017;31:2503-2514.
    PubMed     Text format     Abstract available


  273. DELL'AVERSANA C, Giorgio C, D'Amato L, Lania G, et al
    miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.
    Leukemia. 2017;31:2315-2325.
    PubMed     Text format     Abstract available


    October 2017
  274. SAID B, Gilles S, Weisdorf D, Rashidi A, et al
    The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia.
    Leukemia. 2017 Oct 31. doi: 10.1038/leu.2017.
    PubMed     Text format    


  275. YAN F, Shen N, Pang JX, Zhao N, et al
    A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.
    Leukemia. 2017 Oct 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  276. TOPP MS, Stelljes M, Zugmaier G, Barnette P, et al
    Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 9. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  277. JERCHEL IS, Hoogkamer AQ, Aries IM, Steeghs EMP, et al
    RAS pathway mutations as predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  278. LI Z, Abraham BJ, Berezovskaya A, Farah N, et al
    APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
    Leukemia. 2017;31:2057-2064.
    PubMed     Text format     Abstract available


  279. MUNIR T, Howard DR, McParland L, Pocock C, et al
    Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Leukemia. 2017;31:2085-2093.
    PubMed     Text format     Abstract available


  280. JU HQ, Zhan G, Huang A, Sun Y, et al
    ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
    Leukemia. 2017;31:2143-2150.
    PubMed     Text format     Abstract available


  281. DUELL J, Dittrich M, Bedke T, Mueller T, et al
    Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
    Leukemia. 2017;31:2181-2190.
    PubMed     Text format     Abstract available


  282. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Text format     Abstract available


    September 2017
  283. FUJITA S, Honma D, Adachi N, Araki K, et al
    Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
    Leukemia. 2017 Sep 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  284. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2017 Sep 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  285. BENEDETTI D, Tissino E, Pozzo F, Bittolo T, et al
    NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-kB pathways.
    Leukemia. 2017 Sep 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  286. JO S, Lee JH, Mattei JJ, Barrett DM, et al
    Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  287. DEL GIUDICE I, Rigolin GM, Raponi S, Cafforio L, et al
    Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low and very-low risk genetic profile.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  288. NADEU F, Clot G, Delgado J, Martin-Garcia D, et al
    Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  289. HOSPITAL MA, Jacquel A, Mazed F, Saland E, et al
    RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  290. SAKURA T, Hayakawa F, Sugiura I, Murayama T, et al
    High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  291. WAIBEL M, Vervoort SJ, Kong IY, Heinzel S, et al
    Epigenetic targeting of Notch1 driven transcription using the HDACi panobinostat is a potential therapy against T cell acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  292. TAKAO S, Chien W, Madan V, Lin DC, et al
    Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  293. MARNETH AE, Prange KHM, Al Hinai ASA, Bergevoet SM, et al
    C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
    Leukemia. 2017 Sep 5. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  294. RINKE J, Muller JP, Blaess MF, Chase A, et al
    Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
    Leukemia. 2017;31:1936-1943.
    PubMed     Text format     Abstract available


  295. KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
    The clonal origins of leukemic progression of myelodysplasia.
    Leukemia. 2017;31:1928-1935.
    PubMed     Text format     Abstract available


  296. SAENZ DT, Fiskus W, Qian Y, Manshouri T, et al
    Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Leukemia. 2017;31:1951-1961.
    PubMed     Text format     Abstract available


  297. RONCHINI C, Brozzi A, Riva L, Luzi L, et al
    PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.
    Leukemia. 2017;31:1975-1986.
    PubMed     Text format     Abstract available


    August 2017
  298. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
    Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Aug 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  299. JYOTSANA N, Sharma A, Chaturvedi A, Scherr M, et al
    RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.
    Leukemia. 2017 Aug 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  300. ZHAO L, Alkadi H, Kwon EM, Zhen T, et al
    The C-terminal multimerization domain is essential for leukemia development by CBFbeta-SMMHC in a mouse knockin model.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  301. TOFT N, Birgens H, Abrahamsson J, Griskevicius L, et al
    Results of NOPHO ALL2008 treatment for patients 1-45 years with acute lymphoblastic leukemia.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  302. PENA-MARTINEZ P, Eriksson M, Ramakrishnan R, Chapellier M, et al
    Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  303. KUMAR B, Garcia M, Weng L, Jung X, et al
    Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
    Leukemia. 2017 Aug 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  304. ARTESI M, Marcais A, Durkin K, Rosewick N, et al
    Monitoring molecular response in adult t-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.
    Leukemia. 2017 Aug 16. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  305. HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
    Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  306. HEHLMANN R, Lauseker M, Saussele S, Pfirrmann M, et al
    Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  307. REITER K, Polzer H, Krupka C, Maiser A, et al
    Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  308. MASCIARELLI S, Capuano E, Ottone T, Divona M, et al
    'Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress'.
    Leukemia. 2017 Aug 4. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  309. RAFIQ S, Purdon TJ, Daniyan AF, Koneru M, et al
    Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
    Leukemia. 2017;31:1788-1797.
    PubMed     Text format     Abstract available


  310. DRENNAN S, D'Avola A, Gao Y, Weigel C, et al
    IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.
    Leukemia. 2017;31:1686-1694.
    PubMed     Text format     Abstract available


    July 2017
  311. KIM HG, LeGrand J, Swindle CS, Nick HJ, et al
    The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  312. YIGIT B, Wang N, Chen SS, Chiorazzi N, et al
    Inhibition of Reactive oxygen species (ROS) limits expansion of chronic lymphocytic leukemia cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  313. TEH TC, Nguyen NY, Moujalled DM, Segal D, et al
    Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  314. GIRARDI T, Vereecke S, Sulima SO, Khan Y, et al
    The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  315. XIA F, Zhang Y, Xie L, Jiang H, et al
    B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  316. SOPPER S, Mustjoki S, Gjertsen BT, Giles F, et al
    NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  317. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
    Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed     Text format    


  318. BECK D, Thoms JAI, Palu C, Herold T, et al
    A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
    Leukemia. 2017 Jul 4. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  319. HOURIGAN CS, Gale RP, Gormley NJ, Ossenkoppele GJ, et al
    Measurable residual disease testing in acute myeloid leukaemia.
    Leukemia. 2017;31:1482-1490.
    PubMed     Text format     Abstract available


  320. CUTLER JA, Tahir R, Sreenivasamurthy SK, Mitchell C, et al
    Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
    Leukemia. 2017;31:1513-1524.
    PubMed     Text format     Abstract available


  321. RIBEIRO ST, Tesio M, Ribot JC, Macintyre E, et al
    Casein kinase 2 controls the survival of normal thymic and leukemic gammadelta T cells via promotion of AKT signaling.
    Leukemia. 2017;31:1603-1610.
    PubMed     Text format     Abstract available


    June 2017
  322. ANGENENDT L, Reuter S, Kentrup D, Benk AS, et al
    An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  323. YABE T, Azuma F, Kashiwase K, Matsumoto K, et al
    HLA-DPB1 mismatch induces a graft-versus-leukemia (GVL) effect without severe acute GVHD after single-unit umbilical cord blood transplantation.
    Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  324. TIAO G, Improgo MR, Kasar S, Poh W, et al
    Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
    Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  325. GAIDZIK VI, Weber D, Paschka P, Kaumanns A, et al
    DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
    Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  326. ZHANG Q, Ball MC, Zhao Y, Balasis M, et al
    Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.
    Leukemia. 2017 Jun 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  327. RIO-MACHIN A, Gomez-Lopez G, Munoz J, Garcia-Martinez F, et al
    The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.
    Leukemia. 2017 Jun 20. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  328. GODWIN CD, Gale RP, Walter RB
    Gemtuzumab ozogamicin in acute myeloid leukemia.
    Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  329. SANTINI V, Allione B, Zini G, Gioia D, et al
    A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
    Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  330. BURNS A, Alsolami R, Becq J, Timbs A, et al
    Whole genome sequencing of chronic lymphocytic leukemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.
    Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  331. MARTINEZ-CUADRON D, Montesinos P, Vellenga E, Bernal T, et al
    Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
    Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  332. PROMOD ST, Johnson DP, Bennett SE, Dennis EM, et al
    HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Jun 5. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  333. HAHN M, Burckert JP, Luttenberger CA, Klebow S, et al
    Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappaB signaling.
    Leukemia. 2017 Jun 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  334. USTUN C, Giannotti F, Zhang MJ, Wang HL, et al
    Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
    Leukemia. 2017;31:1408-1414.
    PubMed     Text format     Abstract available


  335. HERNDON TM, Chen SS, Saba NS, Valdez J, et al
    Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
    Leukemia. 2017;31:1340-1347.
    PubMed     Text format     Abstract available


  336. YAN F, Shen N, Pang JX, Zhang YW, et al
    Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.
    Leukemia. 2017;31:1434-1442.
    PubMed     Text format     Abstract available


  337. CHENG G, Liu F, Asai T, Lai F, et al
    Loss of p300 accelerates MDS-associated leukemogenesis.
    Leukemia. 2017;31:1382-1390.
    PubMed     Text format     Abstract available


  338. RODMAN C, Almeida-Porada G, George SK, Moon J, et al
    In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells.
    Leukemia. 2017;31:1398-1407.
    PubMed     Text format     Abstract available


  339. CARTER MJ, Cox KL, Blakemore SJ, Turaj AH, et al
    PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
    Leukemia. 2017;31:1423-1433.
    PubMed     Text format     Abstract available


    May 2017
  340. HALPERN AB, Othus M, Huebner EM, Buckley SA, et al
    Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  341. HA JS, Do YR, Ki CS, Lee C, et al
    Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  342. PATEL B, Przychodzen B, Thota S, Radivoyevitch T, et al
    Genomic determinants of chronic myelomonocytic leukemia.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  343. HEILMANN AM, Schrock AB, He J, Nahas M, et al
    Novel PDGFRB fusions in childhood B and T acute lymphoblastic leukemia.
    Leukemia. 2017 May 29. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  344. MA Z, Zhao X, Huang J, Jia X, et al
    A critical role of periostin in B-cell acute lymphoblastic leukemia.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  345. BERNSON E, Hallner A, Sander FE, Wilsson O, et al
    Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  346. HINZE L, Moricke A, Zimmermann M, Junk S, et al
    Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  347. CHEN L, Mao H, Zhang J, Chu J, et al
    Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
    Leukemia. 2017 May 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  348. PAN J, Yang J, Deng B, Zhao X, et al
    High efficacy and safety of low dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Leukemia. 2017 May 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  349. ROSSETTI C, Picardi E, Ye M, Camilli G, et al
    RNA editing signature during myeloid leukemia cell differentiation.
    Leukemia. 2017 May 9. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  350. HASAN K, Yu J, Chen L, Cui B, et al
    Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  351. YU J, Chen L, Chen Y, Hasan K, et al
    Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
    Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  352. SLINGER E, Thijssen R, Kater AP, Eldering E, et al
    Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  353. LONG J, Fang WY, Chang L, Gao WH, et al
    Targeting HDAC3, new partner protein of AKT in the reversal of chemo-resistance in acute myeloid leukemia via DNA damage response.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  354. GUNNARSSON N, Hoglund M, Stenke L, Sandin F, et al
    No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia-a population-based study in Sweden.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  355. EIRING AM, Page BDG, Kraft IL, Mason CC, et al
    Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Leukemia. 2017;31:1253-1254.
    PubMed     Text format    


  356. LEROY E, Constantinescu SN
    Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition.
    Leukemia. 2017;31:1023-1038.
    PubMed     Text format     Abstract available


  357. KAZIANKA L, Drucker C, Skrabs C, Thomas W, et al
    Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
    Leukemia. 2017;31:1117-1122.
    PubMed     Text format     Abstract available


  358. MALANI D, Murumagi A, Yadav B, Kontro M, et al
    Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
    Leukemia. 2017;31:1187-1195.
    PubMed     Text format     Abstract available


  359. LIU TH, Tang YJ, Huang Y, Wang L, et al
    Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin.
    Leukemia. 2017;31:1079-1086.
    PubMed     Text format     Abstract available


    April 2017
  360. CAZZANIGA G, Bisanti L, Randi G, Deandrea S, et al
    Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster.
    Leukemia. 2017 Apr 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  361. ROSENQUIST R, Ghia P, Hadzidimitriou A, Sutton LA, et al
    Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: Updated eric recommendations.
    Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  362. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
    Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  363. KONGTIM P, Adekola K, Milton DR, Ramlal R, et al
    Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Leukemia. 2017 Apr 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  364. HAN SH, Kim SH, Kim HJ, Lee Y, et al
    Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
    Leukemia. 2017 Apr 11. doi: 10.1038/leu.2017.
    PubMed     Text format    


  365. JONES D, Woyach JA, Zhao W, Caruthers S, et al
    PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  366. SILVA P, Neumann M, Schroeder MP, Vosberg S, et al
    Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  367. HEATH EM, Chan SM, Minden MD, Murphy T, et al
    Biological and clinical consequences of NPM1 mutations in AML.
    Leukemia. 2017;31:798-807.
    PubMed     Text format     Abstract available


  368. VALENT P, Sotlar K, Blatt K, Hartmann K, et al
    Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
    Leukemia. 2017;31:788-797.
    PubMed     Text format     Abstract available


  369. SCHUTZ C, Inselmann S, Sausslele S, Dietz CT, et al
    Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
    Leukemia. 2017;31:829-836.
    PubMed     Text format     Abstract available


    March 2017
  370. HEROLD S, Kuhn M, Bonin MV, Stange T, et al
    Donor cell leukemia-Evidence for multiple pre-leukemic clones and parallel long term clonal evolution in donor and recipient.
    Leukemia. 2017 Mar 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  371. ANADON C, van Tetering G, Ferreira HJ, Moutinho C, et al
    Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  372. COSSON A, Chapiro E, Bougacha N, Lambert J, et al
    Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: Analysis of the central role of XPO1.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  373. MONTALBAN-BRAVO G, Huang X, Naqvi K, Jabbour E, et al
    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Text format    


  374. WALKER CJ, Eisfeld AK, Genutis LK, Bainazar M, et al
    No evidence for microsatellite instability in acute myeloid leukemia.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  375. KAYSER S, Krzykalla J, Elliott MA, Norsworthy K, et al
    Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  376. ZHOU H, Mak PY, Mu H, Mak DH, et al
    Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  377. EISFELD AK, Mrozek K, Kohlschmidt J, Nicolet D, et al
    The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  378. POZZO F, Bittolo T, Vendramini E, Bomben R, et al
    NOTCH1 mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin-1 and ribosome associated components.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  379. KOEFFLER HP, Leong G
    Preleukemia: one name, many meanings.
    Leukemia. 2017;31:534-542.
    PubMed     Text format     Abstract available


  380. SAENZ DT, Fiskus W, Manshouri T, Rajapakshe K, et al
    BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Leukemia. 2017;31:678-687.
    PubMed     Text format     Abstract available


  381. QAZILBASH MH, Wieder E, Thall PF, Wang X, et al
    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
    Leukemia. 2017;31:697-704.
    PubMed     Text format     Abstract available


  382. STRUSKI S, Lagarde S, Bories P, Puiseux C, et al
    NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Leukemia. 2017;31:565-572.
    PubMed     Text format     Abstract available


  383. STENGEL A, Kern W, Haferlach T, Meggendorfer M, et al
    The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Leukemia. 2017;31:705-711.
    PubMed     Text format     Abstract available


  384. MCCRACKEN AN, McMonigle RJ, Tessier J, Fransson R, et al
    Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
    Leukemia. 2017;31:669-677.
    PubMed     Text format     Abstract available


  385. EDELMANN J, Tausch E, Landau DA, Robrecht S, et al
    Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
    Leukemia. 2017;31:734-738.
    PubMed     Text format    


    February 2017
  386. MEDEIROS BC, Fathi AT, DiNardo CD, Pollyea DA, et al
    Isocitrate dehydrogenase mutations in myeloid malignancies.
    Leukemia. 2017;31:272-281.
    PubMed     Text format     Abstract available


  387. BURNETT AK, Russell NH, Hills RK, Kell J, et al
    A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
    Leukemia. 2017;31:310-317.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: